Related Experiment Video
Updated: Dec 13, 2025
02:14
Underwater Endoscopic Injection Sclerotherapy for Gastroesophageal Varices
Published on: August 1, 2025
1.0K
Long-acting Release Octreotide for Pediatric Upper Gastrointestinal Bleeding
I Malla1, S López1, L Busquet2
1Unidad de Hepatología, servicio de Gastroenterología, Hospital de Pediatría Prof. Dr. J.P. Garrahan, Buenos Aires, Argentina.
Revista Chilena De Pediatria
|July 31, 2020
Summary
Long-acting release octreotide (OCT-LAR) offers a new treatment option for pediatric patients experiencing upper gastrointestinal bleeding (UGIB) due to portal hypertension (PHT) when conventional therapies fail. This monthly injection successfully managed bleeding in an infant, showing promise for similar challenging cases.
Area of Science:
- Pediatric Hepatology
- Gastroenterology
- Pharmacology
Background:
- Upper gastrointestinal bleeding (UGIB) in pediatric patients with portal hypertension (PHT) presents significant management challenges, especially when endoscopic or surgical interventions are not feasible.
- Intravenous octreotide is a standard treatment, but long-acting release octreotide (OCT-LAR) offers a promising alternative for sustained therapy.
Observation:
- An infant with recurrent UGIB due to extrahepatic portal vein malformation required frequent blood transfusions and intravenous octreotide.
- Due to the inapplicability of endoscopic or surgical treatments, monthly intramuscular OCT-LAR was initiated.
Findings:
- The infant received ten months of intramuscular OCT-LAR treatment without any recurrence of bleeding episodes.
- No adverse events related to OCT-LAR administration were observed during the treatment period.
Implications:
- This case highlights the potential efficacy and safety of OCT-LAR as a therapeutic option for pediatric UGIB secondary to PHT in complex cases.
- OCT-LAR may provide a viable alternative for managing pediatric patients with PHT-related UGIB when conventional treatment modalities are contraindicated or unsuccessful.
Related Concept Videos
01:24Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
1.1K
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
1.1K
01:26Peptic Ulcer Disease IV: Management
309
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
309
01:25Peptic Ulcer Disease V: Surgical Management and Nursing Care
689
Surgical management and nursing care are crucial in treating Peptic Ulcer Disease (PUD). Here is an organized and enhanced overview of the surgical interventions and the associated nursing care for PUD:
Surgical Interventions for Peptic Ulcer Disease
Surgical Interventions for Peptic Ulcer Disease
689
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
148
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
148
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
176
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
176
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
131
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
131